Cargando…

Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers

Background: Clinically, it is still challenging to differentiate aggressive from non-aggressive prostate cancers (Pca) by non-invasive approaches. Our recent studies showed that overexpression of alpha (1-6) fucosyltransferase played an important role in Pca cells. In this study, we have investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Qing Kay, Chen, Li, Ao, Ming-Hui, Chiu, Joyce Hanching, Zhang, Zhen, Zhang, Hui, Chan, Daniel W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279190/ https://www.ncbi.nlm.nih.gov/pubmed/25553114 http://dx.doi.org/10.7150/thno.10349

Ejemplares similares

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA
por: Wang, Ce, et al.
Publicado: (2019)

Characterisation of the main PSA glycoforms in aggressive prostate cancer
por: Gratacós-Mulleras, Anna, et al.
Publicado: (2020)

HSP27/Menin Expression as New Prognostic Serum Biomarkers of Prostate Cancer Aggressiveness Independent of PSA
por: Bourefis, Asma, et al.
Publicado: (2022)

Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis
por: Wang, Wenying, et al.
Publicado: (2014)

Overexpression of Periostin in Stroma Positively Associated with Aggressive Prostate Cancer
por: Tian, Yuan, et al.
Publicado: (2015)

Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer
por: Fujita, Kazutoshi, et al.
Publicado: (2016)

Serum lipid profiles and aggressive prostate cancer
por: Li, Yanjing, et al.
Publicado: (2015)

Analysis of serum protein glycosylation by a differential lectin immunosorbant assay (dLISA)
por: Li, Danni, et al.
Publicado: (2013)

Correction: Overexpression of Periostin in Stroma Positively Associated with Aggressive Prostate Cancer
por: Tian, Yuan, et al.
Publicado: (2015)

Urinary glycoproteins associated with aggressive prostate cancer
por: Dong, Mingming, et al.
Publicado: (2020)

A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer
por: Song, Jin, et al.
Publicado: (2021)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
por: Lipianskaya, Julia, et al.
Publicado: (2014)

Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer
por: Burdelski, Christoph, et al.
Publicado: (2015)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality
por: Sullivan, J, et al.
Publicado: (2015)

Urinary marker panels for aggressive prostate cancer detection
por: Lih, Tung-Shing Mamie, et al.
Publicado: (2022)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer
por: Lehrer, S, et al.
Publicado: (2002)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Association of prostate volume with incidence and aggressiveness of prostate cancer
por: Al-Khalil, Shadi, et al.
Publicado: (2016)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

A population study of fasting time and serum prostate-specific antigen (PSA) level
por: Lau, Cheryl K, et al.
Publicado: (2014)

Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors
por: Li, Qing Kay, et al.
Publicado: (2021)

Neuroendocrine and Aggressive-Variant Prostate Cancer
por: Spetsieris, Nicholas, et al.
Publicado: (2020)

Biomarkers of Aggressive Prostate Cancer at Diagnosis
por: Boehm, Brock E., et al.
Publicado: (2023)

Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness
por: Schnoeller, Thomas J., et al.
Publicado: (2017)

The association between serum lipid profile and the prostate cancer risk and aggressiveness
por: Suh, Jungyo, et al.
Publicado: (2023)

Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis
por: Huang, Yan, et al.
Publicado: (2018)

ANO7 is associated with aggressive prostate cancer
por: Kaikkonen, Elina, et al.
Publicado: (2018)

Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men
por: Coric, Jozo, et al.
Publicado: (2015)

Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models
por: Chen, Ming, et al.
Publicado: (2021)

Mitochondrial mutations drive prostate cancer aggression
por: Hopkins, Julia F., et al.
Publicado: (2017)

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
por: Filella, Xavier, et al.
Publicado: (2016)

PROSTATE-SPECIFIC ANTIGEN (PSA) VALUES IN PATIENTS WITH LOW- AND HIGH-RISK PROSTATIC ADENOCARCINOMA
por: Mašić, Silvija, et al.
Publicado: (2019)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kejm2keg4a14qt4n6kdeq01pms